KR20140111185A - Composition comprising extract of polygonatum for inhibiting cell aging - Google Patents

Abstract

The present invention relates to a composition comprising a polygonatum extract for inhibiting cell aging. The composition, comprising the polygonatum extract having an excellent effect of inhibiting cell aging as an active ingredient, can be used for preventing age-related diseases, such as skin aging, rheumatoid arthritis, osteoarthritis, hepatitis, chronic damage to skin tissues, arteriosclerosis, prostatic hyperplasia, or liver cancer.

Description

[0001] The present invention relates to a composition for inhibiting cell senescence comprising polygonatum for inhibiting cell aging,

The present invention relates to a composition for inhibiting cell senescence comprising the extract of Aspergillus oryzae, and to a composition for inhibiting cell senescence comprising a Aspergillus oryzae extract which can be usefully used for aging-related diseases.

The delay in the aging process, without degenerative disease, healthy and long-lasting without disease is an ongoing effort to find a substance that inhibits aging by the wind of all people. Oxidation by active oxygen species such as superoxide, hydrogen peroxide, hydroxyl group and singlet oxygen is one of the factors promoting aging. Free radicals generated by the metabolites of reactive oxygen species act on proteins, biomembranes, and DNA in vivo and cause oxidative damage. Many studies have been conducted on antioxidant components to suppress these effects, Researches are being actively conducted at home and abroad to search for new materials having action. However, since the aging phenomenon is not only caused by oxidation but is known to be influenced by numerous factors such as telomerase, cell replication ability, gene damage and recovery ability, it is necessary to evaluate the antioxidative effect of natural products and drugs, A method of using aging is needed.

Cell senescence is a phenomenon in which normal somatic cells can no longer divide after a certain number of divisions, contributing to the aging of individuals and tissues, and is an important mechanism for inhibiting abnormal cell proliferation and cancer formation. Cell senescence is caused by the shortening of the telomere, which is the end of the chromosome, due to repeated somatic cell division, or by the increased activity of cancer gene or cancer suppressor gene, excessive oxidative stress, cytotoxic substances such as ultraviolet radiation or radiation, And the like.

The senescence-associated β-galactosidase (SA-β-gal) activity increases with the morphological features that aged cells become larger, flattened, increase in heterochromatin in the nucleus, (IGFBPs), interleukin-6 (interleukin-6), and transgene-like growth factor-binding proteins (IGFBPs) (TGF-beta), interferon, and the like.

Cell senescence not only contributes to the aging of individuals and tissues, but also plays an important role in the pathogenesis of various diseases. Aging cells are frequently observed in inflammatory lesions such as rheumatoid arthritis, osteoarthritis, hepatitis, chronic skin injured tissue, and arteriosclerotic vascular tissue. In addition, cell senescence is observed in proliferative hyperplasia, hepatitis, and liver cancer.

As the aging cells accumulate, the aging cells do not divide well. Therefore, not only the damaged tissues are properly restored but also the enzymes that decompose the surrounding tissues or the inflammatory cytokines are secreted, accelerating the damage of the tissues. Contributes to the pathogenesis.

Since cellular aging is considered to be an essential cause of aging, efforts have been made to develop methods for delaying cellular aging. Among them, some researches have been conducted to search for substances capable of regulating cell senescence and to utilize them for the prevention and treatment of diseases.

Some of the substances known to regulate cell senescence include resveratrol, which is known to increase SIRT1 activity, and retinoic acid, which is used to delay cellular aging in keratinocytes. In addition, studies have been reported on the identification of substances capable of regulating cell senescence from plant extracts and their use in cosmetics and health functional foods.

 On the other hand, it is a perennial plant of Liliaceae that grows in the temperate zone of the northern hemisphere. In spring, it eats young leaves and roots for food. Especially, root has the strong action, , Weakness in the spleen (脾胃 弱 weak), pulmonary tuberculosis and has been known for the purpose of interpolation (complementary), acne and pesticide. In the oriental medicine, it mainly prescribes the tongue, diabetes, relief, hyperhidrosis, and polyuria. In the private sector, the bruise is finely changed.

Previous studies on Dandelion have shown that the methanol extract of Dandelion root significantly inhibits the cAMP phosphodiesterase and the percentage of phagocytosis of the macrophage in the ethanol extract of Dandelion root And increased index and increased proliferation of hemolysin and lymphocyte have been reported.

In addition, it has been shown that it is used for the treatment and prevention of liver cancer by using donggulle, it is used as a complex for each disease, it is used for reproduction of pyrogenesis and is used for male infertility and diet. However, However, there is insufficient study on the efficacy of the extracts.

DISCLOSURE OF THE INVENTION The present invention was conceived in order to solve the above problems, and it was found that, in researching herbal medicine extracts effective for inhibiting cell senescence, it was found that the extract of Dandelion extract has excellent cell senescence inhibitory effect, And to provide a composition for inhibiting cell senescence.

In order to solve the above-described problems,

A composition for inhibiting cell senescence comprising, as an active ingredient, an extract of Aspergillus oryzae from any one or more selected from the group consisting of Polygonatum.

According to a preferred embodiment of the present invention, the extract may be extracted from Polygonatum odoratum var. Pluriflorum for variegatum Y. N. Le.

According to another preferred embodiment of the present invention, the above extract can be extracted from the root of Rootgrass.

According to another preferred embodiment of the present invention, the Dandelion extract may inhibit SA- [beta] -galactosidase activity.

According to another preferred embodiment of the present invention, the donguloe extract may inhibit the aging of fibroblast (HDF).

According to another preferred embodiment of the present invention, the extract can be extracted with at least one solvent selected from the group consisting of water, alcohol, ethyl acetate, chloroform and hexane.

According to another preferred embodiment of the present invention, the composition may contain Dulgilloe extract at a concentration of 5 to 130 μg / ml.

Further, the present invention provides a health functional food comprising the composition for inhibiting cell senescence comprising the above-described extract of Aspergillus oryzae as an active ingredient.

In addition, the present invention provides a pharmaceutical composition comprising a composition for inhibiting cell senescence, which comprises the above-described Dandelion extract as an active ingredient.

In addition, the present invention provides a cosmetic composition comprising a composition for inhibiting cell senescence comprising the above-described extract of Aspergillus oryzae as an active ingredient.

The composition for inhibiting cell senescence comprising the extract of Dangongleae which is excellent in the inhibition of cell senescence of the present invention is useful as an agent for preventing senescence such as skin aging, rheumatoid arthritis, osteoarthritis, hepatitis, chronic skin damaged tissue, arteriosclerosis, And the like.

1 is a graph showing the results of MTT analysis in fibroblasts (HDF) and vascular endothelial cells (HUVEC).
2 is an optical microscope photograph and a graph showing evaluation of the ability to inhibit SA-β-gal activity in fibroblast (HDF).

Hereinafter, the present invention will be described in more detail.

As described above, Danggulra has been conventionally used for reducing blood sugar level, for the treatment and prevention of liver cancer, for use as a complex for each disease, for use in male infertility and diet, etc. However, No results were reported.

Accordingly, the present invention provides a composition for inhibiting cell senescence comprising, as an active ingredient, an extract of Aspergillus oryzae, which is extracted from at least one selected from the group consisting of Polygonatum (Polygonatum).

In the present invention, MTT assay was performed on a composition containing the extract of Dunguryuloe as an active ingredient, and it was confirmed that there was no cytotoxicity, cell viability was increased, and SA-β-galactosidase (Senescence-associated β-galactosidase Was inhibited. It was confirmed that the extract of Dandelion extract directly inhibits cell senescence.

 The species of the Polygonatum plant include Polygonatum odoratum var. Pluriflorum Ohwi, P. odoratum var. Pluriflorum for variegatum YNLee, P. odoratum (Miller) Druce var. Maximowiczii Koidz, P. involucratum Maxim, P. humile Fischer ex. Maxim and the like can be used alone or in combination thereof, more preferably P. odoratum ver. pluriflorum for. variegatum YNLee) extract may be most effective in inhibiting cell senescence.

It is preferable that the extract is extracted from the root. Most of the other parts of the roots may have insufficient cell aging inhibitory effect.

The extract can be extracted with a solvent such as water, alcohol, ethyl acetate, chloroform or hexane, or more preferably a C _1-4 lower alcohol. The extract may be applied by a general solvent extraction method using the above-mentioned solvent, or it may be a fraction purified by using column chromatography. The method for producing the extract according to the present invention can be applied to any plant extraction method known to those of ordinary skill in the art. For example, extraction with water, alcohol or mixed solvent, extraction with hot water or room temperature But is not limited thereto.

The composition containing the extract of Danguryu extract as an active ingredient did not show cytotoxicity in cells such as fibroblasts (HDF) and vascular endothelial cells (HUVEC), but significantly increased cell proliferation. Inhibited senescence-associated β-galactosidase activity and inhibited cell senescence. In particular, it can be confirmed that the extract of Dandelion (Dandelion) has a remarkably superior cell aging inhibitory effect in fibroblast (HDF) (see Table 2 and FIG. 2).

The composition for inhibiting cell senescence of the present invention may contain the Dangguul extract at a concentration of 5 to 130 μg / ml. The solvent of the composition is not particularly limited as long as it does not interfere with the cell aging inhibitory effect of Dandelion's extract, and more preferably water, ethanol, propyl alcohol, DMSO and the like. When the concentration of the extract of Dunguryul extract is less than 5 μg / ml, the effect of inhibiting SA-β-galactosidase activity is insufficient and the effect of inhibiting cell senescence is poor. When the concentration exceeds 130 μg / ml, There is a problem that the efficiency is lowered. The concentration of the Dangongleae extract composition having no cytotoxic effect and exhibiting an excellent cell senescence inhibiting effect may be more preferably 5 to 30 μg / ml.

In addition, the present invention provides a pharmaceutical composition comprising the composition for inhibiting cell senescence, which comprises the extract of Aspergillus oryzae as an active ingredient.

The pharmaceutical composition can be administered to mammals such as rats, mice, livestock, humans, and the like through various routes including oral, transdermal, subcutaneous, intravenous or muscular. In addition, the pharmaceutical composition comprising the composition for inhibiting cell senescence comprising the extract of Dangguul extract according to the present invention as an active ingredient can be formulated into various formulations. In the case of formulation, it may be formulated using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants which are usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient (e.g., starch, sucrose, lactose and gelatin) Can be mixed and prepared. In addition to simple excipients, lubricants can also be used. Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions and syrups. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances and preservatives . Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. Examples of the non-aqueous solution and suspension include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a suppository base, glycerol, gelatin and the like may be used.

The dosage of the pharmaceutical composition may be varied depending on the age, sex, condition of the subject, the degree of absorption of the active ingredient in the body, the rate of inactivation and the rate of excretion, and the drugs used in combination. A daily dose that can be used without side effects can be administered in single or divided doses in an amount of 0.1 to 100 mg / kg.

When a pharmaceutical composition comprising a composition for inhibiting cell senescence comprising the extract of Aspergillus oryzae as an active ingredient of the present invention is administered to a human body, it can be safely used because it is a natural extract, so that there is less concern about side effects than other synthetic drugs.

In addition, the present invention provides a health functional food comprising a composition for inhibiting cell senescence comprising the extract of Aspergillus oryzae as an active ingredient. There is no particular limitation on the kind of the health functional food containing the composition for inhibiting cell senescence that contains the extract of the present invention as an active ingredient, and examples thereof include meat, sausage, bread, chocolate, candy, snack, confection, , Other noodles, gums, dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages and vitamin complexes.

 The health food may be used in combination with other food or food additives other than the Dandelion extract, and may be suitably used according to a conventional method. For example, in order to prevent the aging of cells containing the extract of Dangguul extract as an active ingredient, Dangguul extract is included as an effective ingredient, and calcium, And then cooled to room temperature to prepare a beverage. In addition, the health supplement for prevention of cell senescence comprising the extract of Dunguryul extract as an active ingredient is a nutritional supplement component (vitamins B1, B2, B5, B6, E and acetic acid ester, nicotinic acid amide), oligosaccharide, 50% ethanol, And the mixture is then dried in a vacuum dryer and then passed through 12 to 14 mesh to uniformly prepare granules. The granules are then extruded in suitable amounts to prepare tablets or powders or hard capsules .

The effective dose of the Dandelion's extract contained in the health food can be used in accordance with the effective dose of the pharmaceutical composition, and the amount of the active ingredient to be mixed can be appropriately determined according to the purpose of use such as preventive or therapeutic treatment. In the case of long-term consumption intended for health and hygiene purposes or for health control purposes, it may be below the above range.

 In addition, the present invention provides a cosmetic composition comprising the composition for inhibiting cell senescence comprising the extract of Aspergillus as an active ingredient. The cosmetic composition comprising the composition for inhibiting cell senescence containing the extract of Aspergillus oryzae as an active ingredient of the present invention may be blended with the extract of Aspergillus oryzae and other components generally added to cosmetics if necessary. Examples of the compounding ingredients that can be added in addition to the above components include a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a plant extract, a pH adjuster, , A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.

The cosmetic composition may be prepared in any form conventionally produced in the art and preferably used in the form of an external ointment for skin, a cleanser, a softening agent, a nutritional lotion, a skin, a lotion, a nutrition lotion, a nutritional cream, Packs, emulsions, oil gels, and the like.

The pharmaceutical composition and the health functional food may be useful for treating or preventing a cell senescence-related disease and particularly for preventing or treating diseases such as rheumatoid arthritis, osteoarthritis, hepatitis, chronic arteriosclerosis, prostatic hyperplasia and liver cancer. But is not limited thereto. In addition, the cosmetic composition may be useful for skin aging and prevention of skin tissue damage.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples should not be construed as limiting the scope of the present invention, and should be construed to facilitate understanding of the present invention.

≪ Example 1 >

1. Preparation of Dangguire extract composition

 The roots of Polygonatum odoratum var. Pluriflorum for. Variegatum YNLee were collected from Seodun - dong, Suwon - si, Gyeonggi - do, Korea, and extracted with distilled water at room temperature after being dried and pulverized. The water in the extract was removed from the freeze dryer . The extract obtained from 63 g of the dried sample was 32 g, and the yield was 50.7%.

The obtained extracts of Dandelion seedlings were dissolved in a solvent DMSO at a concentration of 100 μg / ml to prepare a dandelion extract composition.

2. Cell culture

Human fibroblasts (HDF) were cultured in a DMEM culture medium containing 10% fetal bovine serum and 1% antibiotic at a density of 1 × 10 ⁵ cells in a 100 mm diameter culture dish, cultured in a 5% carbon dioxide incubator at 37 ° C. Respectively. When 80-90% of the cells were grown on the bottom of the culture dish, the cells were treated with 2.5 × Trypsin-EDTA solution and subcultured. Cells in umbilical cord blood were cultured in the same manner using EGM-2 as a culture medium.

 The population doubling (PD) was examined by the following equation.

PD = log ₂ F / log ₂ I (F = number of cells last, I = number of cells first)

The cells used in the experiment were 40 times in the case of human fibroblasts and 30 times or less in the cord blood.

≪ Example 2 >

The extract was prepared in the same manner as in Example 1, except that the extract of Dingleberry was dissolved in a solvent DMSO at a concentration of 10 μg / ml to prepare a Dingleberry extract composition.

<Experimental Example 1> Cytotoxicity measurement

1. Cell culture and treatment with extracts

In a 50-ml tube, 5,000 cells / ml of fibroblasts and 10,000 cells / ml of cord blood cells in the DMEM medium containing 10% fetal bovine serum and 1% antibiotic were added to each well of a 96-well culture vessel 100 μl each was dispensed. Finally, 500 fibroblasts and 1,000 cells were placed in each well and cultured in a 5% CO 2 incubator at 37 ° C for one day. 100 μl of DMEM medium containing 10% fetal bovine serum and 1% antibiotic and EGM-2 medium were added to each well, and then the dunguloe extract composition of the above example was treated.

Meanwhile, dimethyl sulfoxide (DMSO) was treated as a negative control, and 5mM N-acetylcysteine and 500mM Rapamycin were treated as a positive control.

2. MTT analysis

After the cells were cultured in a 5% CO 2 incubator at 37 ° C. for 3 days, the degree of cell growth was confirmed by MTT method. 50 μl of 0.1% MTT (3- (4,5-dimethylthiazol-2yl) -2,5-diphenyltetrazolium bromide) solution was added to each well of a 96-well culture vessel and incubated for 3 hours at 37 ° C in a 5% CO 2 incubator After removing the culture medium and MTT solution, 100 μl of dimethyl sulfoxide was added and the resulting crystals were dissolved. The absorbance was measured at 550 nm using a microplate reader. The percentage (% ) Are shown in Table 1 and Fig.

&Lt; Experimental Example 2 > Evaluation of cytotoxicity of SA-β-galactosidase activity through cell staining

1. Induction of cell aging by adriamycin

Adriamycin is a type of anticancer drug that kills cells at high concentrations but is known to induce cell senescence at low concentrations. Human umbilical cord blood cells were plated at a density of 1.5 × 10 ⁵ cells in a 100 mm diameter culture dish and cultured in a 5% carbon dioxide incubator at 37 ° C. for 3 days. The cell culture medium was removed and the cells were washed twice with DMEM containing 1% After washing, 500 nM adriamycin was treated for 4 hours.

2. Cell culture and treatment

The cells treated with adriamycin for 4 hours were separated from the culture dish with trypsin-EDTA and the cells were placed in a 24-well culture container. In EGM-2 culture medium containing 10% fetal bovine serum and 1% antibiotic in 50 ml tubes, umbilical cord blood cells were added to each well of the culture container. Finally, 5000 cells were placed in 24-well culture vessels and cultured in a 5% CO 2 incubator at 37 ° C for one day. DMEM medium supplemented with 10% fetal bovine serum and 1% antibiotics and EGM-2 medium were added to each well, and then the Dangguul extract composition was treated.

Meanwhile, dimethyl sulfoxide (DMSO) was treated as a negative control, and 5mM N-acetylcysteine and 500mM Rapamycin were treated as a positive control.

3. Staining of SA-β-galactosidase activity

After the cells were cultured in a 5% carbon dioxide incubator at 37 ° C. for 3 days after the treatment, the effect of the extract of Dandelion on the inhibition of cell senescence was examined by SA-b-gal active staining. Cells aged by SA-β-gal staining are stained cytoplasmically blue.

After 3 days of treatment, the cells were washed twice with phosphate buffer, fixed with 3.7% paraformaldehyde for 1 minute, and then fixed. The cells were stained with SA-b-gal staining solution (40 mM citric acid / phosphate [pH 5.8], 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, 2 mM MgCl ₂ , X- Was added, and the mixture was wrapped in a silver foil and reacted at 37 캜 for 18 hours. After washing twice with phosphate buffered saline (PBS), the cells were stained with 1% ezine solution for 1 minute. When crystals were formed, the crystals were dissolved by DMSO and removed. After washing twice with phosphate buffer, blue-stained cells were observed under an optical microscope. The degree of SA-β-gal activity was determined by counting the number of cells stained blue in the cytoplasm among 50 to 100 cells in total, and the results are shown in Table 2 and FIG.

Cell proliferation (%) Fibroblast (HDF) Vascular endothelial cells (HUVEC) Example 1 91.3 ± 4.7 - Example 2 - 92.2 ± 28.3 Cont 100 ± 0 100 ± 0 DMSO 91.0 ± 8.9 91.1 ± 19.4 NAC 91.5 ± 10.4 96.9 ± 12.2 Rapamycin 90.6 ± 4.6 73.2 ± 6.3

In the case of fibroblasts, the extract of Dangwolle according to the above example did not show the cytotoxic effect and it was confirmed that the cell proliferation was significantly increased. And that the vascular endothelial cells did not show cytotoxicity at 10 μg / ml.

SA-β-gal staining (%) Fibroblast (HDF) Example 1 45.5 ± 13.6 Example 2 50.9 ± 6.4 cont 67.2 ± 21.1 DMSO 70.5 ± 10.6 NAC 48.5 ± 18.0 Rapamycin 41.8 ± 15.0

It was shown that the dendriticum extract composition according to the Example exhibited excellent SA-β-gal activity and showed excellent cell aging inhibitory effect.

Hereinafter, formulation examples of the pharmaceutical composition containing the extract of Dangongleae according to the present invention will be described, but the present invention is not to be construed as limiting the present invention.

&Lt; Formulation Example 1 > Preparation of powders

300 mg of Dangguul extract, 100 mg of lactose and 10 mg of talc were mixed and filled into airtight bags to prepare powders.

&Lt; Formulation Example 2 > Preparation of tablet

The tablets were prepared by mixing 50 mg of Danguryu extract, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate, followed by tableting according to a conventional preparation method.

&Lt; Formulation Example 3 > Preparation of capsules

The capsules were prepared by mixing 50 mg of Danguryu extract, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate according to a conventional capsule preparation method, and filled in gelatin capsules.

&Lt; Formulation Example 4 > Preparation of injection

(2 mL) per 50 mL of ampoule, 50 mg of sterilized distilled water for injection, and a proper amount of pH adjuster were prepared according to the usual injection preparation method.

&Lt; Formulation Example 5 > Preparation of liquid agent

100 mg of Dangguul extract, 10 g of isomerized sugar and 5 g of mannitol were added to an appropriate amount of purified water to dissolve the lemon flavor, and the mixture was mixed with purified water to adjust the total volume to 100 ml. Then, And sterilized to prepare a liquid preparation.

Hereinafter, an example of a formulation of a health functional food containing the extract of Danguryu of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically explained.

&Lt; Formulation Example 6 > Preparation of health functional foods

(Vitamin A acetate: 70,, vitamin E: 1.0 mg, vitamin B: 0.13 mg, vitamin B: 0.15 mg, vitamin B 6: 0.5 mg, vitamin B 12: 0.2 쨉 g, vitamin C: 10 mg), biotin (Ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, potassium phosphate monobasic 15 mg, calcium phosphate dibasic calcium phosphate 0.5 mg), and fumaric acid 55 mg, potassium citrate (90 mg), calcium carbonate (100 mg) and magnesium chloride (24.8 mg) were mixed to prepare a granule, and a health food was prepared according to a conventional method.

Hereinafter, formulation examples of the cosmetic composition containing the extract of Dangongleae according to the present invention will be described, but the present invention is not intended to be limited thereto but will be specifically described.

&Lt; Formulation Example 7 > Preparation of essence

Ethyl alcohol 4.00 wt%

Methyl paraben 0.10 wt%

Fragrance 0.10 wt%

Hydrotreated castor oil 0.60 wt%

DL-a-tocopheryl acetate 0.02 wt%

Glycerin 5.00 wt%

1,3-butylene glycol 3.00 wt%

0.20% by weight of hydroxyethylcellulose

Xanthan gum 0.40 wt%

0.02 wt% of E. D. T. A-2Na,

Fish-collagen 4.00 wt%

Dongulla extract composition 0.5 ~ 2.0 wt%

Distilled water balance

&Lt; Formulation Example 8 > Preparation of Cleansing Foam

6.5% by weight stearic acid

Myristic acid 28.0 wt%

3.0% by weight of self-emulsifiable glycerin monostearate

5.0% by weight of propylene glycol

Concentrated glycerin 10.0 wt%

Sodium hydroxide 7.0 wt%

0.1% by weight of sodium ethylenediaminetetraacetate

15.0% by weight &lt; tb &gt;

Fragrance

Purified water balance

Claims (10)

A composition for inhibiting cell senescence comprising, as an active ingredient, an extract of Aspergillus oryzae from any one or more selected from the group consisting of Polygonatum (Polygonatum). The method according to claim 1,
Wherein the extract is extracted from Polygonatum odoratum var. Pluriflorum for variegatum YNLee. The method according to claim 1,
Wherein the extract is extracted from a root of a mulberry tree. The method according to claim 1,
The composition for inhibiting cell senescence is characterized by inhibiting SA-β-galactosidase activity. The method according to claim 1,
The composition for inhibiting cell senescence is characterized by inhibiting aging of fibroblast (HDF). The method according to claim 1,
The composition for inhibiting cell senescence is extracted with at least one solvent selected from the group consisting of water, alcohol, ethyl acetate, chloroform and hexane. The method according to claim 1,
Wherein the composition comprises Dulgile extract at a concentration of 5 to 130 μg / ml. A health functional food comprising a composition for inhibiting cell senescence comprising the extract of Aspergillus oryzae according to any one of claims 1 to 7 as an active ingredient. 8. A pharmaceutical composition comprising a composition for inhibiting cell senescence comprising the extract of Aspergillus oryzae according to any one of claims 1 to 7 as an active ingredient. 8. A cosmetic composition comprising a composition for inhibiting cell senescence comprising the extract of Dangwoo-do according to any one of claims 1 to 7 as an active ingredient.

Images